By Cancer Clinical Trial Specialist / Myelofibrosis Neoplasms Blog / 0 Comments


Myelofibrosis Fast Facts
Myelofibrosis Fast Facts
  1. Myelofibrosis (MF) is a rare bone marrow cancer and is actually a type of chronic leukemia.
  2. MF usually develops slowly, with no symptoms for many years. If symptoms develop, the most common are continuing fatigue, feeling of fullness below the ribs on the left side, pale skin, and night sweats.
  3. Treatments for MF include blood transfusions, chemotherapy, spleen removal, and more.
  4. MF only occurs in 1.5 out of every 100,000 people and is most common in those over 60.
  5. Around 50% of MF patients have a JAK2 mutation in their DNA. This mutation is the focus of targeted treatments.
Myelofibrosis Hopeful Highlights
Myelofibrosis Hopeful Highlights
  1. There are close to 100 Myelofibrosis clinical trials currently taking place in the United States! These trials will help us better understand and treat this rare disease.
  2. A recent analysis showed that patients treated with the targeted therapy ruxolitinib had a 47% lower mortality rate than those not. New targeted therapies are being studied!
  3. Survival of MF is steadily improving! A recent study found the median survival has increased by at least 2 years since 1980.

More Details: Myelodysplastic Syndrome and Myelofibrosis

Free Matching to Cancer Clinical Trials

  • Your match report contains a detailed list of cervical cancer clinical trials that you may be eligible to enroll in to receive unique and nonconventional treatment. Standard treatment is not the only option.
  • A patient advocate will review your report with you to answer any questions or concerns you may have and assist with enrollment if you decide to move forward with a trial.
  • There’s no need to travel to a clinical trial site until the enrollment process is complete.

Our number one priority is creating positive outcomes for cancer patients. Let us help you today.

Write a Comment

Your email address will not be published. Required fields are marked *